DK108491D0 - NUCLEOSIDES AND NUCLEOSIDALALOGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE RELATIONSHIPS - Google Patents

NUCLEOSIDES AND NUCLEOSIDALALOGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE RELATIONSHIPS

Info

Publication number
DK108491D0
DK108491D0 DK911084A DK108491A DK108491D0 DK 108491 D0 DK108491 D0 DK 108491D0 DK 911084 A DK911084 A DK 911084A DK 108491 A DK108491 A DK 108491A DK 108491 D0 DK108491 D0 DK 108491D0
Authority
DK
Denmark
Prior art keywords
formula
carbon
nucleosidalalogs
nucleosides
relationships
Prior art date
Application number
DK911084A
Other languages
Danish (da)
Other versions
DK108491A (en
Inventor
Roelf Datema
Zsuzanna Maria Ilona Kovacs
Karl Nils Gunnar Johansson
Bjorn Gunnar Lindborg
Goeran Bertil Stening
Bo Frederik Oeberg
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of DK108491D0 publication Critical patent/DK108491D0/en
Publication of DK108491A publication Critical patent/DK108491A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A compound of formula (I), wherein the radicals A, X, R<1>, R<2>, and R<3> are defined as follows: A: formula (a) or formula (b); X: (a) O; (b) S; (c) CH2; R<1>: H; alkyl containing 1-3 carbon atoms; -CH=CH2; -CH=CH-CH3; -CH2-CH=CH2; formula (II); -C=CH; R<2>: H; or R<2> constitutes together with R<3> a carbon-carbon bond; R<3>: H; F; Cl; Br; I; N3; CN; C=CH; OH; OCH3; CH2OH; and when R<3> is F; Cl; Br; I; N3; CN; C=CH; OH; OCH3 or CH2OH it may have either the cis-configuration or trans-configuration relative to the hydroxymethyl function at position 4', or R<3> constitutes together with R<2> a carbon-carbon bond, and therapeutically acceptable salts thereof, for use in therapy, in particular for the treatment of HIV virus infections.
DK108491A 1987-04-16 1991-06-07 NUCLEOSIDES AND NUCLEOSIDALALOGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE RELATIONSHIPS DK108491A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8701605A SE8701605D0 (en) 1987-04-16 1987-04-16 NOVEL MEDICINAL COMPOUNDS
CA000580141A CA1336088C (en) 1987-04-16 1988-10-14 1-(3'-substitued-2', 3'-dideoxy-d-ribofuranosyl) thymine and uracil

Publications (2)

Publication Number Publication Date
DK108491D0 true DK108491D0 (en) 1991-06-07
DK108491A DK108491A (en) 1991-06-07

Family

ID=25672174

Family Applications (3)

Application Number Title Priority Date Filing Date
DK696988A DK168443B1 (en) 1987-04-16 1988-12-15 Pyrimid-2-on-1-yl compounds, pharmaceutical preparations which comprise these compounds, and a process for preparing the compounds
DK108491A DK108491A (en) 1987-04-16 1991-06-07 NUCLEOSIDES AND NUCLEOSIDALALOGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE RELATIONSHIPS
DK104994A DK104994A (en) 1987-04-16 1994-09-13 Use of Beta-Anomeric Compounds for the Preparation of Pharmaceuticals for the Treatment or Prevention of HIV or Hepatitis B Virus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK696988A DK168443B1 (en) 1987-04-16 1988-12-15 Pyrimid-2-on-1-yl compounds, pharmaceutical preparations which comprise these compounds, and a process for preparing the compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK104994A DK104994A (en) 1987-04-16 1994-09-13 Use of Beta-Anomeric Compounds for the Preparation of Pharmaceuticals for the Treatment or Prevention of HIV or Hepatitis B Virus

Country Status (9)

Country Link
JP (1) JPH01503069A (en)
AT (1) ATE115958T1 (en)
AU (1) AU614082B2 (en)
CA (1) CA1336088C (en)
DE (1) DE3852531T2 (en)
DK (3) DK168443B1 (en)
HU (1) HU211547A9 (en)
SE (1) SE8701605D0 (en)
WO (1) WO1988008001A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8629892D0 (en) * 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US4950758A (en) * 1988-01-20 1990-08-21 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US5175292A (en) * 1988-01-20 1992-12-29 Regents Of The University Of Minnesota Intermediates for the preparation of dideoxycarbocyclic nucleosides
US5631370A (en) * 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
WO1989008115A1 (en) * 1988-02-24 1989-09-08 Institut De Recherches Chimiques Et Biologiques Ap NEW DERIVATIVES OF DEOXY-2'-URIDINE SUBSTITUTED IN THE 5, 3' OR 5' POSITION BY ACYLATED alpha-AMINO GROUPS, PROCESS FOR OBTAINING THEM AND DRUGS CONTAINING THEM
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
US5198539A (en) * 1988-08-19 1993-03-30 Burroughs Wellcome Co. 5'-esters of 2',3'-dideoxy-3'-fluoro-5-ethynyluridine
FI95384C (en) * 1989-04-06 1996-01-25 Squibb Bristol Myers Co Process for the preparation of 3'-deoxy-3'-substituted methyl nucleosides and intermediates used in the process
FR2648045B1 (en) * 1989-06-13 1991-09-27 Centre Nat Rech Scient ALPHA ANOMERIC OLIGONUCLEOTIDE COMPOUNDS INHIBITING REPLICATION OF RETROVIRUSES
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
ES2253732T3 (en) * 1989-09-15 2006-06-01 Southern Research Institute 2'-DEOXI-4'-TIORIBONUCLEOSIDS AS ANTIVIRAL AND ANTI-TARGET AGENTS.
US5591722A (en) * 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
US5521163A (en) * 1990-07-13 1996-05-28 University Of Birmingham Antiviral pyrimidine nucleosides and methods for using same
SE9003151D0 (en) * 1990-10-02 1990-10-02 Medivir Ab NUCLEOSIDE DERIVATIVES
JP2960164B2 (en) * 1990-11-13 1999-10-06 バイオケム ファーマ インコーポレイテッド Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes having antiviral properties
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
DE69232816T2 (en) * 1991-11-26 2003-06-18 Isis Pharmaceuticals Inc INCREASED FORMATION OF TRIPLE AND DOUBLE HELICOS FROM OLIGOMERS WITH MODIFIED PYRIMIDINES
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5612319A (en) * 1994-05-31 1997-03-18 Medivir Ab Postexposure prevention of HIV infection or seroconversion
JPH10501217A (en) * 1994-05-31 1998-02-03 メディヴィル・アクチボラグ Stop after exposure to HIV
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US5869493A (en) 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
BR9908270A (en) 1998-02-25 2004-06-29 Univ Emory 2-Fluoro-nucleosides, pharmaceutical compositions and their uses
CN1646141B (en) 2000-10-18 2014-06-25 吉利德制药有限责任公司 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
AP2009004812A0 (en) 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor
JP6270742B2 (en) * 2013-01-10 2018-01-31 塩野義製薬株式会社 Method for producing cross-linked nucleic acid derivative

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD75084A (en) *
US3116282A (en) * 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
FR2040177A1 (en) * 1969-01-31 1971-01-22 Robugen Gmbh 2-deoxyribosyl-uracil derivs
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
DE2918260A1 (en) * 1979-05-07 1980-11-27 Robugen Gmbh 5-alkyl-5'-deoxy-uridine deriVs. use - for normalising cancerous cell functions and accelerating wound healing
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
DE2930904A1 (en) * 1979-07-30 1981-02-19 Kailash Kumar Dr Gauri Antitumour use of 5-alkyl-pyrimidine nucleoside derivs. - as potentiators of 5-fluoro-uracil
DE3002197A1 (en) * 1980-01-22 1981-07-23 Robugen Gmbh Pharmazeutische Fabrik Esslingen A.N., 7300 Esslingen 5-Alkyl- and 5-alkenyl-uracil and -cytidine nucleoside derivs. - prepd. e.g. by reaction of 5'-chloro-5'-deoxy cpds. with ammonia
DE3045375A1 (en) * 1980-12-02 1982-07-01 Robugen Gmbh Pharmazeutische Fabrik Esslingen A.N., 7300 Esslingen 5-Substd. pyrimidine nucleoside derivs. - useful as antiviral agents
DE3229169A1 (en) * 1982-08-05 1984-02-09 Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen Use of 5-alkylpyrimidine nucleosides and their derivatives as cytostatics
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
DK166805B1 (en) * 1985-03-16 1993-07-19 Wellcome Found THE THREO ISOMER OF 3'-AZIDO-3'-DEOXYTHYMIDINE FOR USING THE TREATMENT OR PROPHYLAXY OF HUMAN RETROVIRUS INFECTIONS, USING THE COMPOUND FOR THE PREPARATION OF A PHARMACEUTICAL PREPARATION OF A MEDICINAL PRODUCT AND NAVE MEDICINE
DE3687069T2 (en) * 1985-03-16 1993-03-25 Wellcome Found USE OF 3'-AZIDO-3'-DEOXYTHYMIDINE FOR TREATING OR PREVENTING HUMAN RETROVIRUS INFECTIONS.
EP0206497B1 (en) * 1985-05-15 1994-07-20 The Wellcome Foundation Limited Therapeutic nucleosides and their preparation
DK167377B1 (en) * 1985-09-17 1993-10-25 Wellcome Found 3'-AZIDOPYRIMIDINE NUCLEOSIDES OR PHARMACEUTICAL ACCEPTABLE SALTS OR ESTERS THEREOF USED FOR TREATMENT OR PROPHYLAXY FOR A HUMAN RETROVIRUS INFECTION

Also Published As

Publication number Publication date
JPH01503069A (en) 1989-10-19
DE3852531T2 (en) 1995-08-10
DE3852531D1 (en) 1995-02-02
DK696988A (en) 1989-01-31
DK104994A (en) 1994-09-13
ATE115958T1 (en) 1995-01-15
SE8701605D0 (en) 1987-04-16
WO1988008001A1 (en) 1988-10-20
DK696988D0 (en) 1988-12-15
AU614082B2 (en) 1991-08-22
CA1336088C (en) 1995-06-27
DK168443B1 (en) 1994-03-28
HU211547A9 (en) 1995-12-28
DK108491A (en) 1991-06-07
AU1689988A (en) 1988-11-04

Similar Documents

Publication Publication Date Title
DK108491D0 (en) NUCLEOSIDES AND NUCLEOSIDALALOGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE RELATIONSHIPS
PH31397A (en) Use of 1,3-oxathiolane nucleoside analogues in thetreatment of hepatitis b.
FI894545A (en) THERAPEUTIC NUCLEOSIDER.
LU91275I2 (en) Entecavir and its pharmaceutically acceptable derivatives - baraclude
ES2133324T3 (en) SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE.
SE9002500D0 (en) PHARMACEUTICAL, NAC CONTAINING COMPOSITION FOR ORAL ADMINISTRATION
FI911286A (en) CHEMICAL FOERENINGAR.
DK324185D0 (en) 2-SUBSTITUTED 1,3-PROPYLIDENDIPHOSPHONATE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS WITH CONTENTS
DK248886A (en) SPIRO-IMIDAZOLIDINE COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
DE69019404D1 (en) Penciclovir derivatives used to treat hepatitis B infections.
GB2122197B (en) Antiviral guanine derivatives
ES2195996T3 (en) CICLOHEXAPEPTIDILO HYDROXIPROPIONITRILE COMPOUNDS.
ES2105599T3 (en) COMPOSITIONS CONTAINING ANALOG COMPOUNDS WHEN ACICLOVIR AND NUCLEOSIDIC ANALOGS REPLACED BY VINYL IN POSITION 2 &#39;USED IN THE TREATMENT OF VIRAL INFECTIONS.
GR1000522B (en) Preparation method of new analogue nucleozites
IT1245631B (en) Use of macrolide compounds as anti-inflammatory agents for the treatment of diseases caused by histamine release
FR2439203A2 (en) BICYCLIC THIAZOLE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
DE3778858D1 (en) 17-BENZYL SPARTEIN DERIVATIVES CONTAINING POSITIVE INOTROP EFFECTIVE PHARMACEUTICAL PREPARATIONS.

Legal Events

Date Code Title Description
ARF Application refused